Systematic review with meta-analysis: risk of post-operative complications associated with pre-operative exposure to anti-tumour necrosis factor agents for Crohn’s disease.

Related Articles Systematic review with meta-analysis: risk of post-operative complications associated with pre-operative exposure to anti-tumour necrosis factor agents for Crohn’s disease. Aliment Pharmacol Ther. 2019 Mar 12;: Authors: Lin YS, Cheng SW, Wang YH, Chen KH, Fang CJ, Chen C Abstract BACKGROUND: Post-operative complications after anti-tumour necrosis agent treatment for Crohn’s disease (CD) have been analysed with conflicting results. AIM: To assess the effects of pre-operative anti-tumour necrosis factor (TNF) therapy on post-operative complications within 30 days post-operatively in patients with CD undergoing abdominal surgery. METHODS: Systematic review with meta-analysis…

Read More

One-year clinical outcomes with biologics in Crohn’s disease: transmural healing compared with mucosal or no healing.

Related Articles One-year clinical outcomes with biologics in Crohn’s disease: transmural healing compared with mucosal or no healing. Aliment Pharmacol Ther. 2019 Mar 10;: Authors: Castiglione F, Imperatore N, Testa A, De Palma GD, Nardone OM, Pellegrini L, Caporaso N, Rispo A Abstract BACKGROUND: While mucosal healing has been proved to predict relevant clinical outcomes in Crohn’s disease (CD), little is known about the long-term significance of transmural healing. AIMS: To prospectively assess the 1-year clinical outcomes in CD patients achieving transmural healing following treatment with biologics, and to compare…

Read More

Clinical decision support improves quality of care in patients with ulcerative colitis.

Related Articles Clinical decision support improves quality of care in patients with ulcerative colitis. Aliment Pharmacol Ther. 2019 Mar 07;: Authors: Jackson B, Begun J, Gray K, Churilov L, Liew D, Knowles S, De Cruz P Abstract BACKGROUND: Decision support tools may facilitate shared decision-making and improve quality of care. AIM: To assess the effectiveness of a decision support tool on improving quality of care in ulcerative colitis. METHODS: A prospective quality of care intervention was conducted at two Australian hospitals comparing out-patient-based ulcerative colitis care with, and without, a…

Read More

Systematic review: outcomes and adverse events from randomised trials in Crohn’s disease.

Related Articles Systematic review: outcomes and adverse events from randomised trials in Crohn’s disease. Aliment Pharmacol Ther. 2019 Mar 03;: Authors: Catt H, Hughes D, Kirkham JJ, Bodger K Abstract BACKGROUND: The suitability of disease activity indices has been challenged, with growing interest in objective measures of inflammation. AIM: To undertake a systematic review of efficacy and safety outcomes in placebo-controlled randomised controlled trials (RCTs) of patients with Crohn’s disease. METHODS: MEDLINE, EMBASE, CINAHL and Cochrane Library were searched until November 2015, for RCTs of adult Crohn’s disease patients treated…

Read More

Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed.

Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed. Aliment Pharmacol Ther. 2019 Mar;49(6):816-817 Authors: Gibson DJ, Ward MG PMID: 30811645 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30811645?dopt=Abstract

Read More

Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy – early promise but more data needed. Authors’ reply.

Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy – early promise but more data needed. Authors’ reply. Aliment Pharmacol Ther. 2019 Mar;49(6):817-818 Authors: Bouguen G, Siproudhis L PMID: 30811643 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30811643?dopt=Abstract

Read More

Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease.

Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2019 Feb 27;: Authors: Bank S, Julsgaard M, Abed OK, Burisch J, Broder Brodersen J, Pedersen NK, Gouliaev A, Ajan R, Nytoft Rasmussen D, Honore Grauslund C, Roug S, Galsgaard J, Sprogøe Høyer Finsen D, Lindby K, Danish IBD Genetics Working Group, Sørensen J, Larsen L, Rohr Andersen M, Brandslund I, Thomassen M, Green A, Bo Bojesen A, Bek Sørensen S, Vogel U, Andersen…

Read More

Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.

Related Articles Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. Aliment Pharmacol Ther. 2019 Feb 19;: Authors: Drobne D, Kurent T, Golob S, Švegl P, Rajar P, Hanžel J, Koželj M, Novak G, Smrekar N, Ferkolj I, Štabuc B Abstract BACKGROUND: Combination treatment with azathioprine for 6-12 months is the preferred strategy for starting infliximab due to improved pharmacokinetics. However, optimised infliximab monotherapy with proactive dose escalations in case of low trough levels is a safer but under-studied…

Read More

Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from the Asia-Pacific region.

Related Articles Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from the Asia-Pacific region. Aliment Pharmacol Ther. 2019 Feb 17;: Authors: Shah SC, Khalili H, Chen CY, Ahn HS, Ng SC, Burisch J, Colombel JF Abstract BACKGROUND: There appear to be differences in risk factor profiles for IBD between Asia-Pacific and Western populations, which might suggest idiosyncrasies in pathogenesis. Recently, sex-based differences in IBD according to the age of diagnosis have been described in Western populations. AIM: Our primary aim was to identify whether sex-based…

Read More

Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study.

Related Articles Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther. 2019 Feb 17;: Authors: Adar T, Faleck D, Sasidharan S, Cushing K, Borren NZ, Nalagatla N, Ungaro R, Sy W, Owen SC, Patel A, Cohen BL, Ananthakrishnan AN Abstract BACKGROUND: The older patient group with inflammatory bowel diseases (IBD) is particularly vulnerable to consequences of disease and therapy-related side effects but little is known about the best treatment options in this population. AIM: To compare safety…

Read More
<< Go Back